Ser856

Site Information
VSQGQRLsPGsyPTV SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 12072874

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 11 , 12 , 13 )
Disease tissue studied:	breast cancer ( 3 , 8 ) , breast ductal carcinoma ( 3 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, surrounding tissue ( 1 ) , breast cancer, triple negative ( 1 , 3 ) , lung cancer ( 5 , 8 ) , non-small cell lung cancer ( 8 ) , non-small cell lung adenocarcinoma ( 5 ) , lymphoma ( 4 ) , Burkitt's lymphoma ( 4 ) , follicular lymphoma ( 4 ) , mantle cell lymphoma ( 4 ) , melanoma skin cancer ( 2 )
Relevant cell line - cell type - tissue:	BJAB (B lymphocyte) ( 4 ) , breast ( 1 , 3 ) , BT-549 (breast cell) ( 8 ) , Calu 6 (pulmonary) ( 8 ) , FL-18 (B lymphocyte) ( 4 ) , FL-318 (B lymphocyte) ( 4 ) , H2009 (pulmonary) ( 8 ) , H2077 (pulmonary) ( 8 ) , H2887 (pulmonary) ( 8 ) , H322M (pulmonary) ( 8 ) , HCC1937 (breast cell) ( 8 ) , HCC366 (pulmonary) ( 8 ) , HCC78 (pulmonary) ( 8 ) , HCC827 (pulmonary) ( 8 ) , HeLa (cervical) ( 11 ) , JEKO-1 (B lymphocyte) ( 4 ) , Jurkat (T lymphocyte) ( 6 , 12 ) , K562 (erythroid) ( 7 , 13 ) , LCLC-103H (pulmonary) ( 8 ) , lung ( 5 ) , MCF-7 (breast cell) ( 8 ) , MDA-MB-231 (breast cell) ( 8 ) , NCEB-1 (B lymphocyte) ( 4 ) , NCI-H1648 (pulmonary) ( 8 ) , OCI-ly1 (B lymphocyte) ( 4 ) , Raji (B lymphocyte) ( 4 ) , RAMOS (B lymphocyte) ( 4 ) , REC-1 (B lymphocyte) ( 4 ) , SU-DHL-4 (B lymphocyte) ( 4 ) , T lymphocyte-blood ( 9 ) , UPN-1 (B lymphocyte) ( 4 ) , WM239A (melanocyte) ( 2 )

Upstream Regulation
Treatments:	antibody ( 9 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
3	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
4	Rolland D, et al. (2014) Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas. Am J Pathol 184, 1331-42 24667141 Curated Info
5	Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96 23911959 Curated Info
6	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
7	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
8	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
9	Ruperez P, Gago-Martinez A, Burlingame AL, Oses-Prieto JA (2012) Quantitative phosphoproteomic analysis reveals a role for serine and threonine kinases in the cytoskeletal reorganization in early T cell receptor activation in human primary T cells. Mol Cell Proteomics 11, 171-86 22499768 Curated Info
10	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
11	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
12	Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46 19690332 Curated Info
13	Stokes M (2008) CST Curation Set: 4605; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info